The Gene Therapies Are Coming – And So Are New Ways To Pay For Them
Executive Summary
Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.
You may also be interested in...
Investment Outlook For Cell And Gene Therapies Is Cautiously Optimistic
Investors at Alliance for Regenerative Medicine’s Investor Day in March 2019 were bullish on cell and gene therapies, but some worry about the market overcrowding.
Bluebird’s Gene Therapy LentiGlobin Coming Into Land In The EU?
Two charities say a positive CHMP opinion has been given to bluebird bio’s transfusion-dependent β-thalassemia gene therapy LentiGlobin at the first meeting of the EMA’s scientific committee at its new home in Amsterdam.
Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.